Basilea Pharmaceutica Ltd (0QNA.L,BSLN.SW,BPMUF) announced a partnership with INCATE or INCubator for Antibacterial Therapies in Europe, an antimicrobial incubator dedicated to supporting the advancement of early-stage anti-infectives. As an industry partner, Basilea brings extensive preclinical, clinical, and commercial expertise in anti-infectives, while also expanding INCATE's scope for the first time to include antifungals—addressing the urgent need for novel antifungal therapies.
Through this collaboration, Basilea will help INCATE identify and support the most promising early-stage innovations, strengthening the link between emerging scientific ideas and real-world medical needs. The partnership aims to transform preclinical antibacterial and antifungal concepts into assets that can be advanced through industry partnerships, bridging the gap between academic innovation and life-saving medicines.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.